Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Klotho Neurosciences, Inc. (KLTO : NSDQ)

• Company Description    Klotho Neurosciences Inc. is a pharmaceutical company. It specializes in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system which are seen as key developments in treating neurodegenerative and age-related disorders. Klotho Neurosciences Inc., formerly known as ANEW MEDICAL INC., is based in NEW YORK. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $0.38 Daily Weekly Monthly 20 Day Moving Average: 752,462 shares Shares Outstanding: 72.54 (millions) Market Capitalization: $27.53 (millions) Beta: 10.05 52 Week High: $2.45 52 Week Low: $0.11 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -18.30% -20.03% 12 Week -31.00% -32.24% Year To Date -21.75% -32.48%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1300 SOUTH BOULEVARD UNIT D - CHARLOTTE,NC 28203 USA ph: 833-931-6330 fax: - None http://www.klothoneuro.com

• General Corporate Information    Officers Joseph A. Sinkule - Chief Executive Officer Jeffrey LeBlanc - Chief Financial Officer Samuel Zentman - Director Riad El-Dada - Director Jon McGarity - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 49876K103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/30/26 Share - Related Items Shares Outstanding: 72.54 Most Recent Split Date: (:1) Beta: 10.05 Market Capitalization: $27.53 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/30/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.69 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 72.22% vs. Previous Quarter: 58.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -201.60 06/30/25 - -325.88 03/31/25 - -1,779.01 ROA 09/30/25 - -171.30 06/30/25 - -242.15 03/31/25 - -275.01 Current Ratio 09/30/25 - 83.69 06/30/25 - 135.73 03/31/25 - 0.29 Quick Ratio 09/30/25 - 83.69 06/30/25 - 135.73 03/31/25 - 0.29 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 0.14 06/30/25 - 0.23 03/31/25 - 0.02 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©